The ulcerative colitis market was valued at USD 7.49 Billion in 2024 driven by the increasing demand for advanced biologics and immunomodulators across the 8 major markets. It is expected to grow at a CAGR of 3.75% during the forecast period of 2025-2034 and attain a market value of USD 10.82 Billion by 2034.
Base Year
Historical Year
Forecast Year
The market is driven by the rising prevalence of the disease and increasing demand for advanced biologics and immunomodulators.
In December 2024, Celltrion received FDA approval for STEQEYMA, a biosimilar for treating ulcerative colitis. Trends such as regulatory approvals for innovative therapies and strategic mergers are fostering the development of effective treatment options, further boosting market growth.
North America is expected to dominate the market, supported by a high prevalence of the disease, advanced healthcare infrastructure, and substantial investment in research and development.
The market is expanding primarily due to the rising number of people suffering from this chronic inflammatory bowel disease, which affects millions globally. A key driver for this expansion is the rising need for sophisticated biologics and immunomodulators. Additionally, innovative oral therapies that provide corticosteroid-free remission are gaining traction. Trends such as regulatory approvals for new treatments and strategic mergers within the industry, signal a promising expansion of the market. These developments reflect a collective effort to enhance treatment options, ultimately striving to improve the quality of life for patients suffering from ulcerative colitis globally.
Rising Prevalence of Ulcerative Colitis Drives Market Growth
The escalating incidence of ulcerative colitis has become a pivotal factor influencing the market growth. In 2023, the global prevalence was reported at approximately 5 million cases, indicating a significant increase in incidence rates across various regions. This is fostering demand for advanced treatment options, accelerating the development and market adoption of biologics and immunomodulators to address this growing healthcare need.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Disease Type
Market Breakup by Route of Administration
Market Breakup by Molecule Type
Market Breakup by Region
Based on the Route of Administration Oral Administration holds a Substantial Market Growth
Based on the route of administration, the market is divided into oral and injectables. Among these, the oral route is expected to dominate the market due to its convenience, ease of use, and patient preference for non-invasive treatments. Innovative oral medications, such as Balsalazide, and Mesalamine, with their potential to deliver effective, corticosteroid-free remission drive the growth of this segment. This segment is poised for significant expansion during the forecast period, largely due to increasing awareness and demand for patient-friendly treatment options.
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan and India. Among these, the United States is projected to dominate the market due to high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development.
Japan will also hold a significant market share due to the presence of key players. For instance, in 2023, Takeda received the approval to manufacture and market Entyvio® subcutaneous injection in Japan, specifically for the maintenance treatment of moderate to severe ulcerative colitis. This approval represents a significant step forward for patients in Japan who are seeking effective management options for their condition.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Established in 1781, Takeda Pharmaceutical is headquartered in Tokyo, Japan. The company has developed Entyvio (vedolizumab), a monoclonal antibody specifically targeting ulcerative colitis and Crohn’s disease. This drug has become a cornerstone therapy for moderate to severe cases of ulcerative colitis, providing patients with improved symptom control and remission rates.
Founded in 1849, Pfizer Inc., headquartered in New York, USA, is a global leader in healthcare innovation. For ulcerative colitis, Pfizer developed Xeljanz (tofacitinib), an oral Janus kinase (JAK) inhibitor approved for moderate to severe cases. This treatment offers patients a corticosteroid-free option for managing inflammation and achieving remission.
Established in 1876, Eli Lilly is headquartered in Indianapolis, USA. The company is focusing on innovative therapies and is advancing Mirikizumab, an IL-23p19 inhibitor designed for treating moderate to severe ulcerative colitis. The therapy targets inflammation pathways, aiming to improve symptom control and long-term outcomes for patients.
Founded in 1996, Novartis AG is based in Basel, Switzerland. Although primarily focused on broader immunology. Novartis is advancing therapies like Zortress (everolimus), which addresses inflammation in various conditions, including ulcerative colitis. Its contributions highlight the company’s commitment to innovation in treating inflammatory bowel diseases.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson, Merck & Co., and Teva Pharmaceutical Industries Ltd.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Disease Type |
|
| Breakup by Route of Administration |
|
| Breakup by Molecule Type |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share